share_log

信達生物(01801.HK)血壓藥IBI3016首次人體臨床一期研究完成首例給藥

Innovent Bio (01801.HK) has completed the first phase I study of its blood pressure drug IBI3016 in humans, with the first dose administered.

AASTOCKS ·  Aug 2 09:49

Innovent Bio (01801.HK) and Sanigen Biotechnology jointly announced the completion of the first-in-human phase I clinical trial of IBI3016, a targeted silencing RNA drug for angiotensinogen (AGT). The first subject has been dosed.

The drug is mainly used to treat hypertension. In December 2023, Innovent Bio and Sanigen Biotechnology reached a strategic cooperation to jointly promote the development of IBI3016. At the same time, Innovent Bio obtained the exclusive rights to future development, production, and commercialization of the drug in different regions.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment